Dananberg Jamie 4
4 · Annexon, Inc. · Filed Feb 23, 2026
Research Summary
AI-generated summary of this filing
Annexon CMO Jamie Dananberg Receives RSU & Option Grants
What Happened Jamie Dananberg, Chief Medical Officer of Annexon, received two compensation awards on February 19, 2026: 56,250 restricted stock units (RSUs) and 225,000 derivative awards (option-style), both reported as acquired at $0. These are grants of equity compensation (not open-market purchases or sales) and had no cash purchase price at grant.
Key Details
- Transaction date: February 19, 2026; Form 4 filed February 23, 2026 (filed within required two business days).
- Awards: 56,250 RSUs (reported at $0) and 225,000 derivative/option-style awards (reported at $0).
- Vesting (footnotes):
- RSUs: 1/3 vest annually on Feb 19, starting Feb 19, 2027, subject to continued service. (Footnote F1)
- Derivative/option: 1/48th vests monthly beginning Feb 19, 2026; fully vested on the 4th anniversary (Feb 19, 2030) subject to continued service. (Footnote F2)
- Shares owned after the transaction: not specified in the provided filing excerpt.
- No sales, 10b5-1 plan, tax-withholding event, or other special codes were indicated in the excerpt.
Context These grants are standard equity compensation for executives — RSUs deliver shares upon vesting and the derivative award vests over time (not an immediate exercise or cash transaction). Because these are awards rather than open-market purchases or sales, they reflect compensation policy rather than a direct insider market signal.
Insider Transaction Report
- Award
Common Stock
[F1]2026-02-19+56,250→ 129,402 total - Award
Stock Option (Right to Buy)
[F2]2026-02-19+225,000→ 225,000 totalExercise: $5.10Exp: 2036-02-19→ Common Stock (225,000 underlying)
Footnotes (2)
- [F1]Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on February 19 of each year, with the first 1/3rd vesting on February 19, 2027, subject to Reporting Person's continuous service with the Issuer as of each such vesting date.
- [F2]1/48th of the shares subject to the option vest on each monthly anniversary measured from February 19, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to Reporting Person's continuous service with the Issuer as of each such vesting date.